Table 1 Clinicopathological features of RGC and GC before and after matching on the propensity score

Gender

0.0088^#

0.864^#

 female

22 (18.64%)

414 (30.07%)

22 (19.47%)

82 (20.20%)

 male

96 (81.36%)

963 (69.93%)

91 (80.53%)

324 (79.80%)

Age (year)

0.0258^#

0.760^#

  ≤ 60

49 (41.53%)

719 (52.21%)

48 (42.48%)

179 (44.09%)

  > 60

69 (58.47%)

658 (47.79%)

65 (57.52%)

227 (55.91%)

Tumor Grade

0.0031^#

0.823^#

 poorly

70 (59.32%)

639 (47.47%)

66 (58.41%)

227 (55.91%)

 moderately

38 (32.20%)

642 (47.70%)

37 (32.74%)

135 (33.25%)

 well

10 (8.47%)

65 (4.83%)

10 (8.85%)

44 (10.84%)

Tumor size

0.0372^#

0.014^#

  ≤ 3

39 (33.05%)

591 (42.92%)

39 (34.51%)

193 (47.54%)

  > 3

79 (66.95%)

786 (57.08%)

74 (65.49%)

213 (52.46%)

Mean of LN Harvested

 < 0.0001*

 < 0.0001*

13.13 ± 9.58

19.57 ± 5.59

13.34 ± 9.67

19.35 ± 5.40

pT stage

0.0103^†

0.484^†

 T1

28 (23.73%)

212 (15.40%)

28 (24.78%)

93 (22.91%)

 T2

12 (10.17%)

412 (29.92%)

12 (10.62%)

49 (12.07%)

 T3

47 (39.83%)

644 (46.77%)

42 (37.17%)

156 (38.42%)

 T4

31 (26.27%)

109 (7.92%)

31 (27.43%)

108 (26.60%)

pN stage

 < 0.001^†

0.294^†

 N0

51 (43.22%)

453 (32.90%)

51 (45.13%)

174 (42.86%)

 N1

27 (22.88%)

256 (18.59%)

25 (22.12)

79 (19.46%)

 N2

17 (14.41%)

285 (20.70%)

17 (15.04)

64 (15.76)

 N3

23 (19.49%)

383 (27.81%)

20 (17.70%)

89 (21.92%)

TNM stage

0.5478^†

0.161^†

 Stage I

39 (33.05%)

350 (25.42%)

39 (34.51%)

150 (36.95%)

 Stage II

22 (18.64%)

457 (33.19%)

20 (17.70%)

110 (27.09%)

 Stage III

57 (48.31%)

570 (41.39%)

54 (47.79%)

146 (35.96%)

pLNR

 < 0.0001^#

 < 0.0001^#

 0

51 (43.22%)

453 (32.90%)

51 (45.13%)

174 (42.86%)

 0〜0.5

32 (27.12%)

592 (42.99%)

28 (24.78%)

184 (45.32%)

  ≥ 0.5

35 (29.66%)

332 (24.11%)

34 (30.09%)

48 (11.82%)